Tilray Medical Engages in Glioblastoma Research Through Clinical Trial in Spain

LOS ANGELES– In a significant stride for the medical cannabis community, Tilray Medical, an affiliate of Tilray Brands, Inc., declared its involvement in a groundbreaking clinical trial slated to delve into the therapeutic potential of medical cannabis against glioblastoma, a particularly aggressive variant of brain cancer.

Set to be orchestrated in Spain, this clinical trial aims to onboard 30 participants across eight neuro-oncology hubs. It bears the distinction of being underwritten by the Medical Cannabis Bike Tour Foundation charity and is a collective endeavor between the esteemed Spanish Research Group of Neuro-Oncology (GEINO) and Complutense University of Madrid.

The onus of supplying pharmaceutical-grade medical cannabis for this pivotal trial rests with Tilray Medical. The undertaking will be guided by the renowned Dr. Juan Manuel Sepúlveda Sánchez from GEINO. The focal point of the study is a Phase I, open-label, multicenter trial. It seeks to incrementally adjust dosages within the same patient to assess the safety and profile of Tilray Medical’s T10:C10 (THC+CBD) blend, used in synergy with temozolomide and radiotherapy for patients diagnosed with Glioblastoma for the first time.

Denise Faltischek, the chief strategy officer at Tilray and the head of its international ventures, elucidated the gravity of this undertaking. “This trial signifies an avenue for us, as a pivotal player in the Canadian cannabis sector, to immerse ourselves deeply into medical research,” she remarked. Faltischek further added, “This is a ray of hope for those grappling with Glioblastoma. Our dedicated involvement underscores our unwavering commitment to medical research and brings us closer to harnessing the holistic therapeutic spectrum of medical cannabis.”

This initiative is not merely a clinical trial in isolation. It symbolizes a decade-long collaboration bridging the chasm between the scientific domain and the medical cannabis fraternity.

Supporting this, Dr. Sepulveda noted, “For over a decade and a half, we’ve garnered compelling biological evidence underscoring the anti-tumor properties of cannabinoids against some of the most malignant brain tumors – the glioblastomas. With this trailblazing clinical trial, we are poised to evaluate the influence of cannabinoids on tumors that have been untouched by any active treatment hitherto.”

The outcomes of this trial are eagerly awaited by the medical and cannabis communities alike, as it may usher in a new era of understanding and potential treatments for severe medical conditions.